A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation
Latest Information Update: 03 Jul 2023
At a glance
- Drugs Galicaftor (Primary) ; Navocaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors AbbVie; AbbVie Germany
Most Recent Events
- 05 Apr 2023 The trial has been discontinued in Romania, according to European Clinical Trials Database record.
- 23 Oct 2022 The trial has been discontinued in Poland, according to European Clinical Trials Database record.
- 22 Jun 2022 Status changed from active, no longer recruiting to completed.